A Clinical Trial to Evaluate the Effects of the Synbiotic Dual Cap® on Gastrointestinal Comfort in Adults Initiating GLP-1 or Dual-Incretin Therapy for Weight Loss.

November 12, 2026 updated by: Epetome

This is a decentralized, single-group, open-label clinical trial evaluating the effects of the Synbiotic Dual Cap® in 40 adults who have initiated GLP-1 or dual-incretin therapy within the preceding 60 days and who are experiencing at least one associated gastrointestinal symptom. All participants will receive the Synbiotic Dual Cap® (1 capsule daily, taken in the morning without food) alongside their existing GLP-1 medication for 12 consecutive weeks.

Participants will complete study-specific questionnaires at four assessment timepoints: Baseline, Week 4, Week 8, and Week 12. No placebo control arm is included; all efficacy comparisons are within-subject against Baseline values. The study is conducted entirely remotely via the Citruslabs digital platform, with the study product shipped directly to participants' homes.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Nevada
      • Las Vegas, Nevada, United States, 89101
        • Citruslabs

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults aged 18-65 years.
  • Have initiated a GLP-1 receptor agonist or dual-incretin medication for weight loss (including but not limited to semaglutide, tirzepatide, or liraglutide) within the last 60 days prior to the date of enrollment.
  • Self-reported experience of at least one gastrointestinal symptom associated with GLP-1 initiation, including nausea, bloating, constipation, diarrhea, or general digestive discomfort, at the time of screening.
  • Currently on a stable GLP-1 dose as directed by their prescribing physician.
  • Willing to take one Synbiotic Dual Cap® daily for 12 consecutive weeks alongside their existing GLP-1 medication and complete all questionnaire assessments at Baseline, Week 4, Week 8, and Week 12.
  • Willing and able to provide informed consent prior to enrollment.
  • In good general health (GLP-1 use and associated weight-related conditions do not disqualify a participant).
  • Reside in the United States.

Exclusion Criteria:

  • Currently pregnant or breastfeeding (or planning to become pregnant during the study period).
  • Currently taking other fibre, probiotic, prebiotic, or synbiotic supplements that cannot be discontinued for the study period.
  • Diagnosed with a chronic gastrointestinal condition requiring active prescription medical management - including Crohn's disease, ulcerative colitis, coeliac disease, GERD, or gastroparesis - that would independently confound GI symptom endpoints.
  • Use of antibiotics or prescription gastrointestinal medications within the past 30 days prior to enrollment, or intentions to use these medications during the study period.
  • Anyone currently participating or planning to participate in another research study during the study period.
  • Currently receiving immunosuppressant therapy of any kind.
  • Currently undergoing cancer treatment or have had a serious illness requiring hospitalization in the last three months.
  • Reside in Hawaii.
  • Known allergy or hypersensitivity to any ingredient in the Synbiotic Dual Cap®.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Synbiotic Dual Cap® Arm

Participants will take 1 capsule each morning, without food and without a hot drink, for 12 consecutive weeks alongside their existing GLP-1 medication.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Overall Gastrointestinal Comfort
Time Frame: Baseline to Week 12

Within-subject change from Baseline in overall gastrointestinal comfort severity, assessed using study-specific questionnaires

Baseline to Week 12
Change in Bowel Regularity
Time Frame: Baseline to Week 12

Within-subject change from Baseline in bowel regularity, assessed using study-specific questionnaires

Baseline to Week 12
Change in Bloating
Time Frame: Baseline to Week 12

Within-subject change from Baseline in bloating severity and frequency, assessed using study-specific questionnaires

Baseline to Week 12
Change in Constipation
Time Frame: Baseline to Week 12

Within-subject change from Baseline in constipation severity and frequency, assessed using study-specific questionnaires

Baseline to Week 12
Change in Diarrhea
Time Frame: Baseline to Week 12

Within-subject change from Baseline in diarrhea severity and frequency, assessed using study-specific questionnaires

Baseline to Week 12
Change in Nausea
Time Frame: Baseline to Week 12

Within-subject change from Baseline in nausea severity and frequency, assessed using study-specific questionnaires

Baseline to Week 12
Change in Post-Meal Fullness Comfort
Time Frame: Baseline to Week 12

Within-subject change from Baseline in comfort with post-meal fullness, assessed using study-specific questionnaires

Baseline to Week 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participant Perception of Effect on Overall Gastrointestinal Comfort
Time Frame: Week 4, Week 8, and Week 12

Participants' self-reported perception of the product's tolerability and effect on overall gastrointestinal comfort, assessed using questionnaires

Week 4, Week 8, and Week 12
Participant Perception of Effect on Bowel Regularity
Time Frame: Week 4, Week 8, and Week 12

Participants' self-reported perception of the product's tolerability and effect on bowel regularity, assessed using questionnaires

Week 4, Week 8, and Week 12
Participant Perception of Effect on Bloating
Time Frame: Week 4, Week 8, and Week 12

Participants' self-reported perception of the product's tolerability and effect on bloating, assessed using questionnaires

Week 4, Week 8, and Week 12
Participant Perception of Effect on Constipation
Time Frame: Week 4, Week 8, and Week 12

Participants' self-reported perception of the product's tolerability and effect on constipation, assessed using questionnaires

Week 4, Week 8, and Week 12
Participant Perception of Effect on Diarrhea
Time Frame: Week 4, Week 8, and Week 12

Participants' self-reported perception of the product's tolerability and effect on diarrhea, assessed using questionnaires

Week 4, Week 8, and Week 12
Participant Perception of Effect on Nausea
Time Frame: Week 4, Week 8, and Week 12

Participants' self-reported perception of the product's tolerability and effect on nausea, assessed using questionnaires

Week 4, Week 8, and Week 12
Participant Perception of Effect on Post-Meal Fullness Comfort
Time Frame: Week 4, Week 8, and Week 12

Participants' self-reported perception of the product's tolerability and effect on post-meal fullness comfort, assessed using questionnaires

Week 4, Week 8, and Week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

February 1, 2027

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe